Advertisement

International Journal of Hematology

, Volume 90, Issue 5, pp 545–552 | Cite as

Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines

  • Junya Kanda
  • Tatsuki Uchiyama
  • Naohisa Tomosugi
  • Masato Higuchi
  • Takashi Uchiyama
  • Hiroshi Kawabata
Original Article

Abstract

Overproduction of hepcidin by interleukin-6 (IL-6) is considered to be the main factor responsible for the development of anemia in inflammatory conditions. Since oncostatin M (OSM), a member of the IL-6 family, plays an important role in immune and inflammatory responses, we assessed the effect of OSM on hepcidin expression, as well as that of leukemia inhibitory factor (LIF), another member of the IL-6 family. We found that hepcidin expression was markedly induced by OSM and LIF in a time- and dose-dependent manner in hepatoma cell lines, and this expression was induced independent of IL-6/IL-6 receptor signaling. Luciferase assay revealed that OSM and LIF stimulated a −1.3-kb hepcidin promoter. This effect was markedly reduced when the signal transducer and activator of transcription (STAT) site of the promoter was mutated, and was almost completely abolished in the presence of AG-490, a Janus kinase (JAK) inhibitor. Hence, the JAK/STAT pathway plays a major role in OSM- and LIF-induced activation of the hepcidin promoter. In conclusion, we demonstrated that OSM and LIF can induce hepcidin expression mainly through the JAK/STAT pathways. Further studies are warranted to evaluate the clinical significance of OSM and LIF in the development of anemia in various inflammatory diseases.

Keywords

Oncostatin M Leukemia inhibitory factor Interleukin-6 Hepcidin 

Notes

Acknowledgments

We thank Dr. Hideyuki Tsuchida (Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan) for measuring the hepcidin-25 levels in the cell culture supernatant. This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a grant from Takeda Science Foundation; and a grant for Project Research from the High-Technology Center of Kanazawa Medical University (H2007-2).

Conflict of interest statement

N.T. declares that he is also the President of Medical Care Proteomics Biotechnology Co. Ltd. (Ishikawa-ken, Japan), a start-up company, the stocks of which are not publicly traded. Other authors declare that they have no conflicts of interest relevant to this paper.

References

  1. 1.
    Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112:219–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88:7–15.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol. 2007;82:934–45.CrossRefPubMedGoogle Scholar
  6. 6.
    Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Ganz T. Hepcidin: a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol. 2005;18:171–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron-regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis. 2007;39:140–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Anderson GJ, Powell LW. HFE and non-HFE hemochromatosis. Int J Hematol. 2002;76:203–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA. 2005;102:1906–10.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K, Torimoto Y, et al. Upregulation of hepcidin by interleukin-1 beta in human hepatoma cell lines. Hepatol Res. 2005;33:198–205.CrossRefPubMedGoogle Scholar
  14. 14.
    Collins HL. Withholding iron as a cellular defence mechanism: friend or foe? Eur J Immunol. 2008;38:1803–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica. 2007;92:857–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol. 1989;9:2847–53.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Linsley PS, Kallestad J, Ochs V, Neubauer M. Cleavage of a hydrophilic C-terminal domain increases growth-inhibitory activity of oncostatin M. Mol Cell Biol. 1990;10:1882–90.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Grenier A, Dehoux M, Boutten A, Arce-Vicioso M, Durand G, Gougerot-Pocidalo MA, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 1999;93:1413–21.PubMedGoogle Scholar
  21. 21.
    Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139:2977–83.PubMedGoogle Scholar
  22. 22.
    Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A. Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol. 2005;43:893–900.CrossRefPubMedGoogle Scholar
  23. 23.
    Suda T, Chida K, Todate A, Ide K, Asada K, Nakamura Y, et al. Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine. 2002;17:335–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol. 1992;148:1731–6.PubMedGoogle Scholar
  25. 25.
    Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003;149:39–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology. 2004;39:635–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21:4033–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106:1864–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43:698–704.CrossRefPubMedGoogle Scholar
  33. 33.
    Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA. 2004;101:9263–5.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Urbanska-Rys H, Wiersbowska A, Stepien H, Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw. 2000;11:443–51.PubMedGoogle Scholar
  35. 35.
    Koskela K, Pelliniemi TT, Rajamaki A, Pulkki K, Remes K. Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. Eur J Haematol. 2000;65:52–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Gearing DP, Gough NM, King JA, Hilton DJ, Nicola NA, Simpson RJ, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 1987;6:3995–4002.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Gough NM. Molecular genetics of leukemia inhibitory factor (LIF) and its receptor. Growth Factors. 1992;7:175–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Brown MA, Metcalf D, Gough NM. Leukaemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine. 1994;6:300–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol. 1993;53:31–58.CrossRefPubMedGoogle Scholar
  42. 42.
    Lorgeot V, Praloran V, Turlure P, Denizot Y. Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies. Leukemia. 1997;11:311–2.CrossRefPubMedGoogle Scholar
  43. 43.
    Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009;4:e4581.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–300.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Junya Kanda
    • 1
  • Tatsuki Uchiyama
    • 1
  • Naohisa Tomosugi
    • 2
  • Masato Higuchi
    • 2
  • Takashi Uchiyama
    • 1
    • 3
  • Hiroshi Kawabata
    • 1
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Proteomics Research Unit, Division of Advanced Medicine, Medical Research InstituteKanazawa Medical UniversityIshikawaJapan
  3. 3.Kitano HospitalThe Tazuke Kofukai Medical Research InstituteOsakaJapan

Personalised recommendations